Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226726 · ClinicalTrials.gov registry record · Phase 1
Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution
A Phase 1 study of Congenital Myasthenic Syndrome, sponsored by The Foundation for Orthopaedics and Regenerative Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 3
- Study locations
NCT07226726: Recruiting Phase 1 study of Congenital Myasthenic Syndrome, sponsored by The Foundation for Orthopaedics and Regenerative Medicine.
NCT07226726 is a Phase 1 study of Congenital Myasthenic Syndrome that is actively recruiting participants, run by The Foundation for Orthopaedics and Regenerative Medicine. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226726, a Phase 1 study of Congenital Myasthenic Syndrome, is actively recruiting participants, sponsored by The Foundation for Orthopaedics and Regenerative Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 3
- Study locations
Study Summary
Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
Conditions Studied
Interventions
- BIOLOGICAL AlloEx exosomes
Study Locations (3)
Florida
- Prodromos Stem Cell Institute - Naples
Texas
- Prodromos Stem Cell Institute - Irving
Other
- Medical Surgical Associates Center - St John's
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
What NCT07226726 shows while recruiting
NCT07226726 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 1 condition, with Congenital Myasthenic Syndrome appearing as the primary indexed condition, and to 1 intervention - of which AlloEx exosomes is the first listed.
NCT07226726 reports a single indexed study location in Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07226726 about?
NCT07226726 is a clinical study titled "Patients With Congenital Myasthenic Syndrome Will be Treated With Mesenchymal Stem Cell Exosome Solution". Patients with Congenital Myasthenic Syndrome will be treated with Mesenchymal Stem Cell Exosome solution.
What is the current status of trial NCT07226726?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-01-01. Estimated completion is 2028-12-31.
What conditions does trial NCT07226726 study?
This clinical trial studies the following conditions: Congenital Myasthenic Syndrome.
What interventions are being tested in trial NCT07226726?
The interventions under investigation include: AlloEx exosomes (BIOLOGICAL).
Who is sponsoring clinical trial NCT07226726?
This trial is sponsored by The Foundation for Orthopaedics and Regenerative Medicine, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226726 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Myasthenic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07226726's enrollment target sits among peer trials
20 1630th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI